eMedicine Specialties > Endocrinology > Metabolic Disorders
Lecithin-Cholesterol Acyltransferase Deficiency: Treatment & Medication
Updated: Sep 18, 2007
- Overview
- Differential Diagnoses & Workup
- Treatment & Medication
- Follow-up
Treatment
Medical Care
Symptomatic treatment for anemia, renal insufficiency, and atherosclerosis is indicated.
- LCAT gene therapy or liver transplantation theoretically would be a treatment of choice to correct the underlying pathophysiology, but neither procedure has been reported.
- Short-term whole blood or plasma transfusion has been tried to replace the LCAT enzyme in some patients with familial LCAT deficiency, but it did not correct anemia, proteinuria, or lipoprotein abnormalities.
- Renal replacement by dialysis is necessary in those individuals who develop kidney failure.
Surgical Care
- Kidney transplantation is indicated in patients with familial LCAT deficiency and renal failure.
- Corneal transplantation is indicated in patients with corneal opacities with severely reduced vision.
Consultations
- Endocrinologist: Consultation should allow accurate diagnosis and dietary therapy to improve the abnormal lipid findings of hypertriglyceridemia and low HDL.
- Ophthalmologist: Schedule follow-up to monitor visual acuity, the presence of papilledema, and the need for interventions such as corneal transplantation.
- Nephrologist: Consultation is useful in the staging and replacement of kidney function if the kidneys become compromised by LCAT deficiency.
Diet
Restriction of fat intake may be advisable in patients with familial LCAT deficiency, but no evidence supports its potential benefits.
Activity
Because of the small but measurable risk of atherosclerosis in persons with LCAT deficiency, exercise, under the guidance of a physician, theoretically would have a role in prevention of this complication.
Medication
Because of the rarity of LCAT deficiency, pharmacologic therapy has not been specifically studied in a systematic fashion.
More on Lecithin-Cholesterol Acyltransferase Deficiency |
| Overview: Lecithin-Cholesterol Acyltransferase Deficiency |
| Differential Diagnoses & Workup: Lecithin-Cholesterol Acyltransferase Deficiency |
Treatment & Medication: Lecithin-Cholesterol Acyltransferase Deficiency |
| Follow-up: Lecithin-Cholesterol Acyltransferase Deficiency |
| References |
| « Previous Page | Next Page » |
References
Bérard AM, Clerc M, Brewer B, Santamarina-Fojo S. A normal rate of cellular cholesterol removal can be mediated by plasma from a patient with familial lecithin-cholesterol acyltransferase (LCAT) deficiency. Clin Chim Acta. Dec 2001;314(1-2):131-9. [Medline].
Elkhalil L, Majd Z, Bakir R, et al. Fish-eye disease: structural and in vivo metabolic abnormalities of high-density lipoproteins. Metabolism. May 1997;46(5):474-83. [Medline].
Hirano K, Kachi S, Ushida C, Naito M. Corneal and macular manifestations in a case of deficient lecithin: cholesterol acyltransferase. Jpn J Ophthalmol. Jan-Feb 2004;48(1):82-4. [Medline].
Kuivenhoven JA, Pritchard H, Hill J, et al. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res. Feb 1997;38(2):191-205. [Medline].
Mertens A, Verhamme P, Bielicki JK, et al. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation. Apr 1 2003;107(12):1640-6. [Medline].
Pritchard PH, Hill JS. Genetic disorders of lecithin:cholesterol acyltransferase. In: Betterridge J, Illingworth R, Sheperd J, eds. Lipoproteins in Health and Disease. 799-814. ed. London, England: Hodder and Stoughton; 1999:799-814.
Santamarina-Fojo S, Hoef J, Assmann G. Lecithin: cholesterol acyltransferase deficiency and fish-eye disease. In: Wonsiewicz M, Noujaim S, Boyle P, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:2817-33.
Further Reading
Keywords
LCAT deficiency, familial lecithin-cholesterol acyltransferase deficiency, familial LCAT deficiency, cholesterol acyltransferase deficiency, fish-eye disease, fish eye disease, high-density lipoprotein, HDL, low-density lipoprotein, LDL, atherosclerosis, renal failure, kidney failure, corneal opacities, visual impairment, hypoalphalipoproteinemia, opaque cornea, corneal opacity, progressive corneal opacification
Treatment & Medication: Lecithin-Cholesterol Acyltransferase Deficiency